Treatment of stage IIIA non-small cell lung cancer

Lary A. Robinson; Henry Wagner; John C. Ruckdeschel

doi:10.1378/chest.123.1_suppl.202S

Treatment of stage IIIA non-small cell lung cancer

Lary A. Robinson
, Henry Wagner
, John C. Ruckdeschel

Research output: Contribution to journal › Review article › peer-review

114 Scopus citations

Abstract

Stage IIIA non-small cell lung cancer represents a relatively heterogeneous group of patients with metastatic disease to the ipsilateral mediastinal (N2) lymph nodes and also includes T3N1 patients. Presentations of disease range from apparently resectable tumors with occult microscopic nodal metastases to unresectable, bulky multistation nodal disease. Controversy abounds as to the optimal treatment of the various stage IIIA subsets, which is fueled by a lack of meaningful, large randomized trials. Multimodality therapy of some type appears to be preferable in stage IIIA patients.

Original language	English (US)
Pages (from-to)	202S-220S
Journal	CHEST
Volume	123
Issue number	1 SUPPL.
DOIs	https://doi.org/10.1378/chest.123.1_suppl.202S
State	Published - 2003

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

All Science Journal Classification (ASJC) codes

Pulmonary and Respiratory Medicine
Critical Care and Intensive Care Medicine
Cardiology and Cardiovascular Medicine

Access to Document

10.1378/chest.123.1_suppl.202S

Cite this

@article{facfa7e4b5b846c084e0c25329641ff3,

title = "Treatment of stage IIIA non-small cell lung cancer",

abstract = "Stage IIIA non-small cell lung cancer represents a relatively heterogeneous group of patients with metastatic disease to the ipsilateral mediastinal (N2) lymph nodes and also includes T3N1 patients. Presentations of disease range from apparently resectable tumors with occult microscopic nodal metastases to unresectable, bulky multistation nodal disease. Controversy abounds as to the optimal treatment of the various stage IIIA subsets, which is fueled by a lack of meaningful, large randomized trials. Multimodality therapy of some type appears to be preferable in stage IIIA patients.",

author = "Robinson, \{Lary A.\} and Henry Wagner and Ruckdeschel, \{John C.\}",

year = "2003",

doi = "10.1378/chest.123.1\_suppl.202S",

language = "English (US)",

volume = "123",

pages = "202S--220S",

journal = "CHEST",

issn = "0012-3692",

publisher = "Elsevier Inc.",

number = "1 SUPPL.",

}

TY - JOUR

T1 - Treatment of stage IIIA non-small cell lung cancer

AU - Robinson, Lary A.

AU - Wagner, Henry

AU - Ruckdeschel, John C.

PY - 2003

Y1 - 2003

N2 - Stage IIIA non-small cell lung cancer represents a relatively heterogeneous group of patients with metastatic disease to the ipsilateral mediastinal (N2) lymph nodes and also includes T3N1 patients. Presentations of disease range from apparently resectable tumors with occult microscopic nodal metastases to unresectable, bulky multistation nodal disease. Controversy abounds as to the optimal treatment of the various stage IIIA subsets, which is fueled by a lack of meaningful, large randomized trials. Multimodality therapy of some type appears to be preferable in stage IIIA patients.

AB - Stage IIIA non-small cell lung cancer represents a relatively heterogeneous group of patients with metastatic disease to the ipsilateral mediastinal (N2) lymph nodes and also includes T3N1 patients. Presentations of disease range from apparently resectable tumors with occult microscopic nodal metastases to unresectable, bulky multistation nodal disease. Controversy abounds as to the optimal treatment of the various stage IIIA subsets, which is fueled by a lack of meaningful, large randomized trials. Multimodality therapy of some type appears to be preferable in stage IIIA patients.

UR - https://www.scopus.com/pages/publications/0037250502

UR - https://www.scopus.com/pages/publications/0037250502#tab=citedBy

U2 - 10.1378/chest.123.1_suppl.202S

DO - 10.1378/chest.123.1_suppl.202S

M3 - Review article

C2 - 12527580

AN - SCOPUS:0037250502

SN - 0012-3692

VL - 123

SP - 202S-220S

JO - CHEST

JF - CHEST

IS - 1 SUPPL.

ER -

Treatment of stage IIIA non-small cell lung cancer

Abstract

UN SDGs

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this